Syantra Advances Cancer Detection with New Funding
In an exciting development for cancer detection and treatment, Syantra, Inc., a cutting-edge precision biotechnology firm, has garnered funding aimed at enhancing the clinical evidence backing its Onco-ID™ cancer detection platform. This new initiative is set to advance important research and collaboration with the Mays Cancer Center at the University of Texas Health Science Center.
Funding Announcement and Collaboration Goals
The support stems from Alberta Innovates, which issued funding through its AICE (Accelerating Innovations into CarE) Market Access program. This funding is not only intended to propel Syantra's recent strides but also to support pivotal pilot studies dedicated to the Onco-ID™: Breast blood test. This test focuses specifically on women identified at an increased risk for breast cancer.
Bridging Innovation with Clinical Validation
Syantra's CEO, Rob Lozuk, expressed pride in receiving the AICE award and emphasized the importance of combining innovative science with available funding to further the mission of early cancer detection. The challenge of breast cancer impacts many lives, and the Onco-ID™ test aims to revolutionize screenings for diverse groups of women.
Impact of the AICE Funding
The grant is set to bolster essential work leading up to FDA filings, as Syantra gears up for a swift entry into the United States market. The strategic funding will expand clinical validation data focusing on women with dense breast tissue—known to present additional screening challenges.
Early Detection through Collaborative Efforts
Dr. Jessica Treviño Jones represents a vital partner in this engagement, serving as a breast medical oncologist at the Mays Cancer Center and directing its Cancer Risk Reduction and Education Clinic. She will be instrumental in recruiting 500 participants for the clinical validation study of the Onco-ID blood test.
Plans for Participant Recruitment and Data Collection
Over the next two years, this collaboration aims to incorporate a diverse group of participants, helping to build a comprehensive data set that will support the commercialization of the Onco-ID™ test. The project not only seeks to validate existing global recruitment efforts but also to gather data that will inform clinical applications.
Recognizing Alberta's Innovators
Tim Murphy, Vice President of Health at Alberta Innovates, praised Syantra as an example of the province's innovators confronting real-world problems. Such collaborations highlight the importance of international partnerships—particularly in pursuing early cancer detection methods that utilize the Onco-ID™ platform.
Looking to the Future
The development of the Onco-ID™ test is closely linked to the body's immune responses, aiming to identify early-stage cancer with greater accuracy. As Syantra prepares for what could be a monumental 2025, all eyes are on the organization as it strives to redefine cancer detection methodologies.
About Syantra
Syantra, a privately held company emerging from Calgary, is comprised of a team of experts in biomedical engineering and medicine, dedicated to pioneering solutions in cancer detection and management. Their innovative platform demonstrates the potential to create lasting impacts in cancer care across various clinical settings.
Frequently Asked Questions
What is the Onco-ID™ cancer detection platform?
The Onco-ID™ platform is a blood test developed by Syantra for early detection of cancer, specifically tailored for women at elevated risk of breast cancer.
How is Syantra collaborating with Mays Cancer Center?
Syantra is working with Dr. Jones at Mays Cancer Center to conduct clinical validation studies involving 500 participants to enhance the early detection of breast cancer.
What will the funding from Alberta Innovates be used for?
The funding will support critical activities leading to FDA filings, expand clinical validation data, and facilitate pilot studies related to the Onco-ID™ breast test.
Why is early detection of breast cancer important?
Early detection significantly increases treatment success rates and can lead to better health outcomes for patients diagnosed with breast cancer.
What is the significance of the AICE funding?
The AICE funding elevates Syantra's research efforts and signifies solid recognition of their innovation, aiding their entry into the U.S. market.
